VTAE +30% AH on phase-1 data for BACE inhibitor: http://www.fiercebiotech.com/story/boehringer-vitae-survive-first-clinical-challenge-crowded-alzheimers-race/2014-10-23 This program is partnered with Boehringer Ingelheim.